Main article

Gen-Probe (San Diego), which in October 2009 completed its $60 million acquisition of Prodesse, has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) to market Prodesse’s molecular test for the detection and differentiation of parainfluenza 1, 2, and 3 viruses, which cause lower respiratory tract infections.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

January 2010 - Table of Contents

DTTR January 2010 (Full PDF Issue)

H1N1 Flu Testing Volume Down 75% Since October

Becton Dickinson Completes $275 Million Acquisition of HandyLab

deCODE Genetics Files for Bankruptcy

FDA Authorizes Emergency Use of H1N1 Flu Tests from Roche, DxNA, TessArae

Gen-Probe Receives FDA Clearance for Prodesse Parainfluenza Test

Medicare Finalizes Decision to Cover HIV Screening

Inside the Diagnostics Industry: H1N1 Virus Activity and Testing Volumes Down From Fall High, but Labs Remain Vigilant

Lab Test Volumes Climb in 2009, G-2 Survey Finds

Cystic Fibrosis Screening Linked to Decreased Disease Incidence

Life Technologies Completes Purchase of BioTrove

Clarient Acquires Applied Genomics

Screening Test Can Identify Newborns With Blood Disorder, JAMA Study Finds

Genetic Findings May Translate to New Test for Lung Cancer

BD Receives Expanded Clearance for STD Tests

IVD Stocks Gain 6%; OraSure Up 20% on Medicare Decision to Cover HIV Testing

G2 Insider (January 2010)